BioHarvest Sciences Q2 revenue jumps on VINIA growth

BioHarvest Sciences Inc. (BHST) reported a 41% year-over-year revenue increase to $8.5 million in Q2, driven by 28% growth in its core VINIA product line and contributions from its CDMO business, while gross margins expanded to 60%. Despite a widened net loss of $4 million primarily due to non-cash finance expenses, the company reiterated its forecast for adjusted EBITDA breakeven in Q4 and expects Q3 revenue of at least $9.1 million, indicating continued operational execution and strategic advancement in key segments.

Analysis

BioHarvest Sciences reported strong operational performance in its second quarter, with revenue growing 41% year-over-year to $8.5 million, meeting company guidance. This growth was primarily fueled by a 28% increase in its core VINIA product line, which now serves 65,000 active users in the US. A key indicator of improving efficiency is the expansion of gross margins to 60% from 52% in the prior year, attributed to enhanced manufacturing scale and yields. While the headline net loss widened to $4.0 million from $0.7 million, this was largely due to non-cash finance expenses related to currency exchange rates, not a decline in operational profitability. The more indicative adjusted EBITDA loss remained relatively stable at $1.3 million. The company's balance sheet strengthened, with cash increasing to $3.7 million. Critically, management reiterated its forecast to achieve adjusted EBITDA breakeven in the fourth quarter and projected Q3 revenue of at least $9.1 million, signaling continued momentum. Strategic progress was also evident in its CDMO business, which secured a new contract and advanced another, supporting its platform's validation and building a robust customer pipeline for the next 6-9 months.

Key Decisions for Investors

• Investors should focus on the strong operational metrics, including the 41% revenue growth and significant gross margin expansion to 60%, while noting the widened net loss was driven by non-cash expenses rather than core business deterioration.
• The primary catalyst to monitor is the company's execution towards its reaffirmed goal of achieving adjusted EBITDA breakeven in Q4 2025, as hitting this target would significantly de-risk the investment.
• Consider the potential for upside from new growth initiatives, particularly the planned electrolyte beverage line and the successful conversion of the CDMO customer pipeline, which could provide meaningful revenue diversification.